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SUMMARY
Recurrent event data are commonly encountered in clinical and epidemiological studies. A major compli-
cation arises when recurrent events are terminated by death. To assess the overall effects of covariates on
the two types of events, we define a weighted composite endpoint as the cumulative number of recurrent
and terminal events properly weighted by the relative severity of each event. We propose a semiparametric
proportional rates model which specifies that the (possibly time-varying) covariates have multiplicative
effects on the rate function of the weighted composite endpoint while leaving the form of the rate function
and the dependence among recurrent and terminal events completely unspecified. We construct appro-
priate estimators for the regression parameters and the cumulative frequency function. We show that the
estimators are consistent and asymptotically normal with variances that can be consistently estimated. We
also develop graphical and numerical procedures for checking the adequacy of the model. We then demon-
strate the usefulness of the proposed methods in simulation studies. Finally, we provide an application to
a major cardiovascular clinical trial.
Keywords: Counting process; Dependent censoring; Intensity function; Inverse probability of censoring weighting;
Mean function; Survival analysis.
1. INTRODUCTION
In clinical and epidemiological studies, a subject can potentially experiencemultiple episodes of an adverse
event, such as headache and pyogenic infection (Fleming and Harrington, 1991). Traditional survival anal-
ysis methods focusing on the time to the first event do not make full use of available data or characterize
the entire clinical experience of the subject. It is statistically more efficient and clinically more meaningful
to consider all recurrent events.
A number of statistical models and methods have been developed to analyze recurrent event data.
Specifically, Andersen and Gill (1982) proposed the multiplicative intensity model by treating recurrent
events as a non-homogeneous Poisson process, under which the risk of recurrence does not depend on the
prior event history. To remove the Poisson assumption, Pepe and Cai (1993), Lawless and Nadeau (1995),
and Lin and others (2000), hereafter referred to as LWYY, proposed to model the marginal rate function,
which is easier to interpret than the intensity function. Prentice and others (1981) considered the hazard
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functions of the gap times between recurrent events, while Wei and others (1989) considered the marginal
hazard function of each recurrent event.
Repeated occurrences of a serious adverse event, such as heart failure (Pfeffer and others, 2003), oppor-
tunistic HIV infection (Vlahov and others, 1991; Abrams and others, 1994), and cancer (Byar, 1980), tend
to cause deterioration of health so that the subject may die during the course of the study. This phenomenon
poses two challenges. First, the presence of a terminal event (i.e., death) invalidates the aforementioned
methods for analyzing recurrent event data. Second, assessing the effects of treatments or other covariates
on the entire clinical experience of a patient would need to take into account both recurrent and terminal
events.
Two major approaches have been suggested to analyze recurrent and terminal events. The first one
deals with the marginal rate or mean function of recurrent events, acknowledging the fact that there is no
recurrent event after the terminal event (Cook and Lawless, 1997; Ghosh and Lin, 2000;Wang and others,
2001; Ghosh and Lin, 2002; Chen and Cook, 2004; Schaubel and others, 2006; Cook and others, 2009).
The second one is the joint modelling for the two types of events (Huang and Wang, 2004; Liu and others,
2004; Ye and others, 2007; Zeng and Lin, 2009; Zeng and Cai, 2010). Both approaches treat recurrent
and terminal events as two separate endpoints. The marginal rate and mean functions are affected by the
distribution of the terminal event. The joint modelling approach assumes that a latent variable captures
the dependence among recurrent events as well as the dependence between recurrent and terminal events,
which is a simplistic and unverifiable assumption. For these reasons, the two approaches have rarely been
used in actual clinical trials.
The current practice is to use the time to the first composite event (i.e, the first recurrent event or the ter-
minal event, whichever occurs first) (Pfeffer and others, 2003; Yusuf and others, 2003; Anand and others,
2009; O’Connor and others, 2009; Zannad and others, 2011). This simple strategy is line with the ICH
guidelines (Lewis, 1999) that “There should generally be only one primary variable” and that “If a single
primary variable cannot be selected from multiple measurements associated with the primary objective,
another useful strategy is to integrate or combine the multiple measurements into a single or composite
variable, using a predefined algorithm.” The first composite event, however, is statistically inefficient and
clinically unsatisfactory because it disregards all the events beyond the first one and does not distinguish
recurrent and terminal events such that a subject who has a hospital admission first is treated the same as
a subject who dies first.
Based on our recent conversations with cardiologists and regulatory statisticians, a weighted composite
endpoint of all recurrent and terminal events, i.e., the cumulative number of recurrent and terminal events
properly weighted by their degrees of severity, is an appealing alternative that is likely to be accepted by
clinicians and regulatory agencies. This endpoint is a natural extension of the current practice of the first
composite event so as to capture all the clinical events experienced by each patient. Compared with the
first composite event, the weighted composite event process is not only statistically more efficient due to
the use of all available data but also clinically more meaningful due to incorporation of the entire clinical
experience of each patient and appropriate weighting of different types of events. This proposal reflects
the recommendation of Neaton and others (2005) to optimally weight components of composite outcomes
and to better use the entire event history of patients. An unweighted version of this composite endpoint
is being used in a major clinical trial on the efficacy of an angiotensin receptor neprilysin inhibitor in
reducing heart failures and cardiovascular death for patients with preserved ejection fraction.
The purpose of this article is to show how to properly analyze the weighted composite event process.We
formulate the effects of treatments and other covariates on the weighted composite event process through a
semiparametric proportional rates model and provide the corresponding inference procedures. In particu-
lar, we derive a non-parametric test statistic for assessing the treatment difference that does not involve any
modelling assumption. The nonparametric nature is highly attractive for regulatory purposes. Because it is
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tempting to apply LWYY to the (unweighted) composite event process, we investigate the potential pitfalls
of this strategy. We demonstrate the superiority of the new methods through simulated and real data.
2. METHODS
Suppose that there are K different types of events, including the terminal event, where K is a fixed positive
integer. For k = 1, . . . , K , let N ∗k (t) denote the cumulative number of the kth type of event the subject has
experienced by time t . We assign the weight ck to the kth type of event according to its relative severity and
define the weighted sum of the K counting processes: N ∗(t) =∑Kk=1 ck N ∗k (t). Let Z(·) denote a p-vector
of possibly time-varying external covariates, and D denote the survival time, i.e., time to the terminal
event. We specify that Z(t) has multiplicative effects on the marginal rate function of N ∗(t), i.e.,
E{dN ∗(t) | Z(t)} = eβTZ(t) dμ0(t), (2.1)
where β is a p-vector of unknown regression parameters, and μ0(·) is an arbitrary increasing function.
Note that the dependence structure among recurrent and terminal events is completely unspecified. For
time-invariant covariates, model (2.1) reduces to the proportional meansmodel: E{N ∗(t) | Z} = eβTZμ0(t),
where μ0(·) is the baseline mean function.
In practice, N ∗(·) and D are subject to right censoring. Let C be the censoring time, which is assumed
to be independent of N ∗(·) and D conditional on Z(·). Write N (t) = N ∗(t ∧ C), X = D ∧ C , and δ =
I (D C), where a ∧ b=min(a, b), and I (·) is the indicator function. For a study with n subjects, the
data consist of {Ni (t), Zi (t), Xi , δi ; t  Xi } (i = 1, . . . , n).
The only available approach to fitting model (2.1) is the LWYY estimating function
n∑
i=1
∫ τ
0
{
Zi (t) −
∑n
j=1 Y j (t)Z j (t) e
βTZ j (t)∑n
j=1 Y j (t) eβ
TZ j (t)
}
dNi (t),
where Y j (t) = I (X j  t), and τ denotes the end of the study. In this approach, which is only applicable
to the unweighted composite event process, death is part of the composite endpoint and also a censoring
variable. This estimating function can be written as
n∑
i=1
∫ τ
0
{
Zi (t) −
∑n
j=1 Y j (t)Z j (t) e
βTZ j (t)∑n
j=1 Y j (t) eβ
TZ j (t)
}{
dNi (t) − Yi (t) eβTZi (t) dμ˜0(t)
}
,
where μ˜0(·) is some positive function. For this estimating function to be unbiased, wemust have E{dN (t) −
Y (t) eβ
TZ(t) dμ˜0(t) | Z(t)} = 0, i.e., E[I (X  t){dN ∗(t) − eβTZ(t) dμ˜0(t)} | Z(t)]= 0. Thus, the LWYY
inference pertains to the conditional rate
E{dN ∗(t) | D  t, Z(t)} = eβTZ(t) dμ˜0(t), (2.2)
where dμ˜0(t) = E{dN ∗(t) | D  t, Z(t) = 0}. The integrated conditional rate does not have a clinical
interpretation and is always greater than the marginal mean because E{dN ∗(t) | D  t} = E{I (D  t)
dN ∗(t)}/P(D  t) = E{dN ∗(t)}/P(D  t).
It is possible for models (2.1) and (2.2) to hold for the same β, in which case LWYY would pro-
vide valid inference on β. For example, suppose that the process N ∗(t) has the intensity function I (D 
t)ξ eβ
TZ(t) dμ∗0(t)with respect to the filtrationFt ≡ σ {N ∗(u), I (D  u), Z(u+), 0 u  t, ξ}, where ξ is
a positive frailty. Assume also that the distribution of the survival time D does not depend on Z(·) or β.
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Then
E{dN ∗(t) | Z(t)} = eβTZ(t)E{ξ P(D  t |ξ)} dμ∗0(t),
and
E{dN ∗(t) | D  t, Z(t)} = eβTZ(t)E(ξ | D  t) dμ∗0(t).
Thus, proportionality holds on both the marginal and conditional rate functions, although the baseline
functions are different. If D depends on Z or the dependence between recurrent events and death cannot
be explained by a simple frailty, then the conditional rate model does not hold and LWYY will estimate a
quantity that is different from β of model (2.1).
To make valid inference for model (2.1), we need to exclude the dependent censoring by death from
the “at-risk” indicators in the estimating function. Specifically, a subject should remain in the risk set until
independent censoring occurs even if the subject dies before the independent censoring time (i.e., D <C).
In other words, the at-risk process is I (C  t) instead of I (X  t). If there is no early withdrawal or loss
to follow-up, then the censoring is all administrative (i.e., caused by the termination of the study) and
the censoring time is known to be the difference between the study end date and the subject’s entry time.
Replacing Y (t) in the LWYY estimating function with I (C  t), we obtain the estimating function
n∑
i=1
∫ τ
0
{
Zi (t) −
∑n
j=1 I (C j  t)Z j (t) eβ
TZ j (t)∑n
j=1 I (C j  t) eβ
TZ j (t)
}
dNi (t), (2.3)
which can be written as
n∑
i=1
∫ τ
0
{
Zi (t) −
∑n
j=1 I (C j  t)Z j (t) eβ
TZ j (t)∑n
j=1 I (C j  t) eβ
TZ j (t)
}{
dNi (t) − I (Ci  t) eβTZi (t) dμ0(t)
}
.
This is an unbiased estimating function because E{dN (t) − I (C  t) eβTZ(t) dμ0(t) | Z(t)} = E[I (C 
t){dN ∗(t) − eβTZ(t) dμ0(t)} | Z(t)]= 0 under model (1).
In most studies, there is random loss to follow-up in addition to administrative censoring, so
that C is not fully observed. Thus, we use the inverse probability of censoring weighting technique
(Robins and Rotnitzky, 1992). Define
w(t) = I (C  D ∧ t)G(t | Z)
G(D ∧ t | Z) ,
where G(t | Z) = P(C  t | Z). Clearly, E{w(t) | Z} =G(t | Z). We estimate w(t) by
ŵ(t) ≡ I (C  D ∧ t)Ĝ(t | Z)
Ĝ(D ∧ t | Z) =
I (C  D ∧ t)Ĝ(t | Z)
Ĝ(X ∧ t | Z) ,
where Ĝ(t | Z) is the estimator of G(t | Z) under the proportional hazards model (Cox, 1972)
λC(t | Z) = λC0 (t) eγ
TZ(t). (2.4)
If Z is discrete, we may set Ĝ(t |Z) to be the Kaplan–Meier estimator for covariate value Z . Replacing
I (C j  t) in (2.3) with
ŵ j (t) ≡ I (C j  Dj ∧ t)Ĝ(t |Z j )
Ĝ(X j ∧ t |Z j )
,
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we obtain an estimating function that allows unknown censoring times
U (β) =
n∑
i=1
∫ τ
0
{
Zi (t) −
∑n
j=1 ŵ j (t)Z j (t) e
βTZ j (t)∑n
j=1 ŵ j (t) eβ
TZ j (t)
}
dNi (t). (2.5)
Let βˆ denote the root ofU (β) = 0, which is obtained by the Newton–Raphson algorithm. The estimator
βˆ is consistent and asymptotically normal with a covariance matrix estimator given in Section S.1 of
supplementary material available at Biostatistics online. We make inference about β or a subset of β by
the Wald method. If Z is the treatment indicator and Ĝ pertains to the treatment-specific Kaplan–Meier
estimator, then the Wald statistic provides a nonparametric test for the equality of the two mean functions
(since there is no modelling assumption under β = 0).
To estimate the baseline mean function μ0(t), we employ a weighted version of the Breslow estimator
μˆ0(t) =
n∑
i=1
∫ t
0
dNi (u)∑n
j=1 ŵ j (u) eβˆ
TZ j (u)
.
This estimator is consistent and asymptotically normal with a covariance function given in Section S.1
of supplementary material available at Biostatistics online. Since μ0(t) is nonnegative, we construct the
confidence interval forμ0(t) based on the log transformation. To be specific, the (1 − α)100% confidence
interval for μ0(t) is given by μˆ0(t) exp{±z1−α/2σ̂ (t)1/2/μˆ0(t)}, where σ̂ (t) is the variance estimator for
μˆ0(t), and z1−α/2 is the (1 − α/2)100th percentile of the standard normal distribution. Incidentally, the
LWYY estimator of μ0(t) is
n∑
i=1
∫ t
0
dNi (u)∑n
j=1 Y j (u) eβˆ
TZ j (u)
,
which overestimates μ0(t) because Y j (t) I (C j  t) for all j and t .
To assess the adequacy of model (2.1), we define Mi (t) =
∫ t
0 wi (u){dNi (u) − eβ
TZi (u) dμ0(u)} and
Mˆi (t) =
∫ t
0 ŵi (u){dNi (u) − eβˆ
TZi (u) dμˆ0(u)}. Because the Mi (·) are mean-zero processes under model
(2.1), we plot the cumulative sum of the Mˆi (·) against the model component of interest. Specifically,
to check the functional form of the j th (time-invariant) covariate, we consider the cumulative-sum process
Wj (x) =
n∑
i=1
I (Z ji  x)Mˆi (τ ),
where Z ji is the j th component of Zi . To check the exponential link function, we consider
Wr (x) =
n∑
i=1
I (βˆTZi  x)Mˆi (τ ).
To check the proportionality assumption, we consider the standardized “score” process
U (t) = 
ˆ−1/2
n∑
i=1
∫ t
0
Zi (u) dMˆi (u),
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where 
ˆ is a covariance matrix estimator for n−1/2U (β). To check the overall fit of the model, we consider
W0(t, z) =
n∑
i=1
I (Zi  z)Mˆi (t).
We show in Section S.2 of supplementary material available at Biostatistics online, that, undermodel (2.1),
all the above processes are asymptotically zero-mean Gaussian processes whose distributions can be
approximated by Monte Carlo simulation along the lines of LWYY. We can graphically compare the
observed cumulative-sum process with a few realizations from its null distribution or perform a numerical
test based on the maximum absolute value of the process.
3. SIMULATION STUDIES
We assess the finite-sample performance of the new methods through extensive simulation studies. We
consider one sequence of recurrent events, along with a terminal event. In order to compare with existing
methods, we focus on the unweighted version of the composite endpoint. It is not trivial to generate the
composite event process that satisfies the proportional means assumption.We outline below our data gener-
ation schemewhile relegating the details to Section S.3 of supplementary material available at Biostatistics
online.
Let N ∗∗(t) be a homogeneous Poisson process with intensity λ0 eβ
TZ , and let τ ∗ be a stopping time
such that there is at least one event in the interval [0, τ ∗]. Then by labeling the last event in [0, τ ∗] as
the terminal event, we have a well-defined composite event process given by N ∗(t) ≡ N ∗∗(t ∧ τ ∗). If the
distribution of τ ∗ is independent of Z and uninformative about β, the optional sampling theorem implies
that
E{N ∗(t) | Z} = λ0 eβTZ E(τ ∗ ∧ t).
Thus, the process satisfies the proportional means assumption. In fact, given some appropriate λ∗ > 0, we
can simulate τ ∗ that follows the exponential distribution with hazard λ∗. Furthermore, we can introduce
a frailty term ξ to the λ0 and λ∗ of each subject so as to induce dependence among the event times of the
same subject. We let λ0 = 0.6 and Z ∼Bernoulli(1/2). Let the administrative censoring time be distributed
as U [3, 6] and the random loss of follow-up be distributed as exponential with hazard 0.1. Let the frailty
term ξ follow the gamma distribution with mean 1 and variance σ 2. Under these conditions, each subject
has an average of 2–3 events, and the censoring rate is ∼30%.
We conduct two sets of simulation studies to compare the new and LWYYmethods for making inference
on β. In the first set, we let λ∗ = 0.1 for all subjects, so that the two treatment groups have the same
distribution of the terminal event. The results are displayed in Table 1. The new estimator βˆ is virtually
unbiased, and its variance estimator accurately reflects the true variation. As expected, LWYY also provides
correct inference since the simulation set-up also conforms to the conditional rate model (2.2).
In the second set of studies, we let the distributions of the stopping time τ ∗ differ between the two
groups, such that the hazards of death are different while the mean functions of N ∗ are the same between
the two groups (i.e., β = 0). Specifically, we generate a homogeneous Poisson process with intensity 0.6
for both groups and label the last event in the time interval [0, 6] as death with probabilities p0 and p1 for
groups 0 and 1, respectively. We let p0 = 0.1 and p1 = 0.2, 0.3, or 0.5. Thus, the mean functions for the
two groups are both 0.6t for t ∈ [0, 6] but their death rates are different. We let the administrative censoring
time be distributed as U [5, 6], let σ 2 = 0, and keep the other conditions the same as before. As shown in
Table 2, the new estimator is approximately unbiased and the corresponding test has correct type I error.
In contrast, the LWYY method is biased and its type I error is inflated; the problem worsens as the death
rates between the two groups become more different and as the sample size increases.
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Table 1. Simulation results comparing the new and LWYY methods in estimating the treatment
difference under equal distributions of death
New LWYY
n σ 2 β Bias SE SEE CP Bias SE SEE CP
100 0 0 0.002 0.158 0.161 0.952 0.002 0.163 0.165 0.951
100 0 0.5 −0.001 0.150 0.150 0.957 −0.002 0.149 0.149 0.946
100 0.25 0 −0.001 0.200 0.198 0.954 0.003 0.205 0.204 0.955
100 0.25 0.5 0.005 0.192 0.190 0.953 0.003 0.191 0.188 0.948
100 0.5 0 −0.003 0.240 0.243 0.953 0.003 0.240 0.239 0.952
100 0.5 0.5 0.007 0.213 0.214 0.957 0.002 0.212 0.212 0.950
200 0 0 0.002 0.111 0.114 0.945 0.002 0.111 0.114 0.956
200 0 0.5 0.001 0.106 0.106 0.951 0.002 0.107 0.109 0.951
200 0.25 0 0.003 0.140 0.141 0.944 −0.002 0.143 0.144 0.945
200 0.25 0.5 0.000 0.130 0.131 0.952 0.005 0.132 0.130 0.946
200 0.5 0 −0.001 0.164 0.162 0.948 0.002 0.168 0.167 0.950
200 0.5 0.5 0.000 0.148 0.146 0.944 0.001 0.156 0.153 0.952
500 0 0 0.001 0.067 0.067 0.951 0.002 0.072 0.071 0.944
500 0 0.5 0.001 0.066 0.064 0.954 0.000 0.069 0.068 0.950
500 0.25 0 0.002 0.093 0.094 0.947 0.002 0.085 0.083 0.945
500 0.25 0.5 0.002 0.088 0.087 0.953 −0.002 0.086 0.089 0.952
500 0.5 0 −0.001 0.101 0.099 0.954 −0.002 0.106 0.108 0.955
500 0.5 0.5 0.000 0.091 0.090 0.948 −0.002 0.097 0.097 0.951
Bias is the bias of the parameter estimator βˆ, SE is the empirical standard error of βˆ, SEE is the empirical mean of the standard
error estimator of βˆ, and CP is the coverage probability of the 95% confidence interval. Each entry is based on 10 000 replicates.
Table 2. Simulation results comparing the new and LWYY methods in estimating
and testing the treatment difference under unequal distributions of death
New LWYY
n p1 Bias Size Bias Size
100 0.2 0.002 0.052 0.017 0.058
100 0.3 −0.004 0.046 0.037 0.108
100 0.5 0.005 0.054 0.133 0.208
200 0.2 0.009 0.053 0.016 0.066
200 0.3 0.006 0.058 0.039 0.204
200 0.5 −0.005 0.052 0.131 0.321
500 0.2 −0.002 0.045 0.018 0.102
500 0.3 0.002 0.048 0.038 0.389
500 0.5 −0.004 0.054 0.132 0.615
Bias is the bias of the parameter estimator, and size is the empirical type I error of the Wald statistic for
testing H0 : β = 0 at the nominal significance level of 0.05. Each entry is based on 10 000 replicates.
We adopt the first simulation set-up to assess the performance of the new and LWYY methods for
estimating the baseline mean function μ0(·). By treating death as censoring, the LWYY method will over-
estimate the mean function. Indeed, LWYY estimates μ˜0(t) = λ0t , which is strictly greater than μ0(t) ≡
λ0E(t ∧ τ ∗) = λ0/λ∗E{1 − exp(−λ∗tξ)}. Simulation results are summarized in Table 3 and are consistent
with the expectations.
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Table 3. Simulation results comparing the new and LWYY methods in estimating the baseline mean
function
New LWYY
n σ 2 t μ0(t) Mean SE SEE CP Mean SE SEE CP
100 0 1 0.571 0.571 0.084 0.082 0.952 0.616 0.092 0.095 0.927
2 1.088 1.085 0.134 0.137 0.953 1.246 0.155 0.158 0.796
3 1.555 1.560 0.175 0.176 0.945 1.900 0.223 0.221 0.610
0.5 1 0.558 0.556 0.106 0.104 0.944 0.590 0.119 0.120 0.923
2 1.041 1.041 0.173 0.170 0.947 1.182 0.208 0.206 0.863
3 1.463 1.461 0.230 0.232 0.950 1.753 0.299 0.301 0.784
200 0 1 0.571 0.570 0.059 0.062 0.950 0.617 0.064 0.067 0.892
2 1.088 1.091 0.099 0.098 0.951 1.250 0.115 0.117 0.681
3 1.555 1.558 0.122 0.124 0.944 1.907 0.158 0.159 0.595
0.5 1 0.558 0.558 0.071 0.070 0.954 0.593 0.079 0.077 0.915
2 1.041 1.042 0.116 0.119 0.951 1.182 0.140 0.139 0.819
3 1.463 1.459 0.167 0.169 0.948 1.750 0.205 0.205 0.641
500 0 1 0.571 0.572 0.038 0.036 0.954 0.610 0.046 0.048 0.828
2 1.088 1.083 0.061 0.062 0.953 1.251 0.070 0.068 0.616
3 1.555 1.559 0.083 0.083 0.951 1.903 0.096 0.097 0.277
0.5 1 0.558 0.554 0.045 0.047 0.945 0.590 0.047 0.049 0.736
2 1.041 1.042 0.077 0.078 0.949 1.177 0.096 0.097 0.656
3 1.463 1.459 0.102 0.103 0.945 1.750 0.131 0.129 0.309
Mean is the empirical mean of μˆ0(t), SE is the empirical standard error of μˆ0(t), SEE is the empirical mean of the standard error
estimator of μ̂0(t), and CP is the coverage probability of the 95% log-transformed confidence interval. Each entry is based on
10 000 replicates.
We also compare the power of the new method using different weighting schemes with the current
practice of performing the Cox regression on the time to the first composite event. The results for the
first simulation set-up are shown in Table S1 of supplementary material available at Biostatistics online.
The power of the new method decreases as the weight on death increases. This is not surprising since the
distributions of death are identical between the two groups. For all weighting schemes, the new method
yields much higher power than the Cox regression.
Next, we consider mis-specified censoring distributions. We use the first simulation set-up but gener-
ate the time to random loss of follow-up L from the proportional odds model: P(L  t |Z)/{1 − P(L 
t |Z)} = eZ (1 − e−0.1t )/e−0.1t . We estimate the censoring distributions by the Kaplan–Meier estimator or
under the Cox model. The results are summarized in Table S2 of supplementary material available at
Biostatistics online. Under the Cox model, the type I error is only slightly inflated, and the power tends to
be higher than the use of the Kaplan–Meier estimator.
Finally, we evaluate the type I error of the supremum tests for model adequacy. The simulation set-up
is the same as the first one except that we let Z1 be the indicator variable and add a continuous vari-
able Z2 that is standard normal. For n = 50, we simulate 1000 datasets with β = (0.5, 0)T. For each
dataset, we obtain 1000 realizations from the null distribution to perform the supremum test at the
nominal significance level of 0.05. We assess the functional form of Z2, the proportionality assump-
tion on Z1, the exponential link function, and the overall goodness of fit. The empirical type I error
rates are 0.045, 0.039, 0.046, and 0.052, respectively. Thus, the goodness-of-fit tests are accurate for
practical use.
398 L. MAO AND D. Y. LIN
4. A REAL EXAMPLE
Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) was a ran-
domized controlled clinical trial to evaluate the efficacy and safety of exercise training among patients
with heart failure (O’Connor and others, 2009). A total of 2331 medically stable outpatients with heart
failure and reduced ejection fraction were recruited between April 2003 and February 2007 at 82 centers
in the USA, Canada, and France. Patients were randomly assigned to usual care alone or usual care plus
aerobic exercise training that consists of 36 supervised sessions followed by home-based training. The
usual care group consisted of 1172 patients (follow-up data not available for 1 patient), and the exercise
training group consisted of 1159 patients. There were a large number of hospital admissions (due to heart
failure, other cardiovascular causes, or non-cardiovascular causes) and a considerable number of deaths in
each treatment arm, as shown in Table S3 of supplementary material available at Biostatistics online.
The primary endpoint was a composite of all-cause mortality and all-cause hospitalization. Secondary
endpoints included the composite of cardiovascular mortality and cardiovascular hospitalization, and the
composite of cardiovascular mortality and heart failure hospitalization. Under the Cox models on the time
to the first event adjusting for heart failure etiology (ischemic or not), the p-values for these three endpoints
were found to be 0.13, 0.14, and 0.06, respectively (O’Connor and others, 2009). This analysis disregarded
all the clinical events that occurred after the first one and attached the same clinical importance to hospi-
talization and death.
To provide a statistically more efficient and clinically more relevant evaluation of the benefits of exer-
cise training, we use the proposed weighted composite event process for death and recurrent hospital-
ization. For each of the three endpoints, we first consider an unweighted version of the composite event
process—each event receives the same weight. To reflect the unequal severity of death versus hospitaliza-
tion, we also consider a weighted version which assigns the weights of 2 and 1 to death and hospitalization,
respectively. Because heart failure is a life-threatening event, we consider another weighting scheme which
assigns the weights of 3, 2, and 1 to cardiovascular death, heart failure, and other cardiovascular hospital-
ization, respectively. These weights are in line with the cardiology literature (e.g., Califf and others, 1990;
Braunwald and others, 1992; Armstrong and others, 2011).
We apply the proportional means model to the aforementioned weighted composite event processes.
Table 4 displays the results on the ratios of the mean frequencies of the weighted composite events between
exercise training and usual care adjusted for heart failure etiology. The p-values for the unweighted com-
posite endpoints of all-cause mortality and all-cause hospitalization, cardiovascular mortality and cardio-
vascular hospitalization, and cardiovascular mortality and heart failure hospitalization are 0.06, 0.087, and
0.022, respectively, which are substantially smaller than the corresponding p-values in the analysis of the
first event. Because treatment differences are more profound for hospitalization than for mortality, assign-
ing more weight to death than hospitalization tends to reduce the level of statistical significance. Because
there are a large number of recurrent hospital admissions, however, the use of the weighted composite
event process (with less weight on hospitalization than on death) still tends to yield stronger evidence for
the benefits of exercise training than the use of the first composite event, especially for the composite of
mortality and heart failure.
We compare the new and LWYY methods in the estimation of the mean functions for the unweighted
composite event process of all-cause mortality and all-cause hospitalization. As shown in Figure 1, the
LWYY estimates of the mean functions are considerably higher than ours. This phenomenon is consistent
with the theory and simulation results.
For further illustration, we apply the proportional means model to the last composite event pro-
cess in Table 4 by adjusting for four additional covariates that were identified to be highly prognostic
(O’Connor and others, 2009). These covariates are duration of the cardiopulmonary exercise test (CPX),
left ventricular ejection fraction (LVEF), Beck Depression Inventory II score (BDI), and history of atrial
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Table 4. Proportional mean regression analysis of the HF-ACTION data under different weighting
schemes
Weights Ratio SE 95% CI p-value
All-cause mortality and all-cause hospitalization
Death= 1 Hospitalization= 1 0.886 0.057 (0.782, 1.004) 0.060
Death= 2 Hospitalization= 1 0.895 0.061 (0.783, 1.023) 0.104
Cardiovascular mortality and cardiovascular hospitalization
Death= 1 Hospitalization= 1 0.892 0.059 (0.784, 1.015) 0.087
Death= 2 Hospitalization= 1 0.906 0.070 (0.779, 1.053) 0.196
Death= 1 Heart failure= 1 Others= 0 0.854 0.059 (0.746, 0.977) 0.022
Death= 2 Heart failure= 1 Others= 0 0.863 0.062 (0.750, 0.994) 0.040
Death= 3 Heart failure= 2 Others= 1 0.862 0.061 (0.750, 0.990) 0.037
Ratio is the estimated ratio of the mean frequencies of the weighted composite events between exercise training and usual
case, SE is the (estimated) standard error for the ratio estimate, and 95%CI is the 95% confidence interval.
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Fig. 1. Estimated mean functions for all-cause mortality and all-cause hospitalization by treatment group for non-
ischemic patients in the HF-ACTION study: the left and right panels pertain to usual care and exercise training,
respectively. The new and LWYY methods are denoted by the solid and dashed curves, respectively.
fibrillation or flutter (AFF). The results on the regression effects are summarized in Table S4 of sup-
plementary material available at Biostatistics online. With the covariate adjustment, the effect of exercise
training is highly significant. Figure S1 of supplementary material available at Biostatistics online pro-
vides an example of predicting the number of events for a patient with given covariate values.
We check the model assumptions by using the diagnostic tools described in Section 2. The supremum
tests for checking the functional forms of the continuous variables CPX, LVEF, and BDI have p-values of
0.523, 0.217, and 0.308, respectively. The supremum tests for checking the proportionality assumptions
on CPX, LVEF, BDI, AFF, HF etiology, and treatment group have p-values of 0.138, 0.328, 0.070, 0.300,
0.105, and 0.256, respectively. The p-value for checking the exponential link function is 0.083. Thus, the
model fits the data reasonably well. A subset of the residual plots are displayed in Figure S2 supplementary
material available at Biostatistics online.
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5. DISCUSSION
The presence of a terminal event poses serious challenges in the analysis of recurrent event data. The exist-
ing methods treating recurrent and terminal events as two separate endpoints have not been well received
by clinicians or regulatory agencies. The nonparametric tests of Ghosh and Lin (2000) have been used
in recent cardiovascular trials (Anand and others, 2009; Rogers and others, 2012), but only as secondary
analysis; none of the other methods seem to have been used in actual clinical trials. The current practice is
to use the first composite event as the primary endpoint. This endpoint disregards the information on the
clinical events beyond the first one and does not distinguish the two types of events. The weighted com-
posite event process is a natural extension of the current measure to enhance statistical power and clinical
relevance. This endpoint is particularly useful when there are several types of recurrent events, some of
which might have too few occurrences to be analyzed separately.
We have proposed a novel proportional rates/means model for studying the effects of treatments and
other covariates on the weighted composite event process and provided the corresponding inference pro-
cedures. We have demonstrated that the proposed inference procedures have desirable asymptotic and
finite-sample properties. We have shown both analytically and numerically that the LWYY approach
always over-estimates the mean function of the (unweighted) composite event process (whether or not
recurrent and terminal events are correlated) and generally yields biased estimation of the regression
parameters.
Although the concept of proportional rates/means is simple and attractive, it is not obvious that the
model can hold for the weighted composite event process. We have shown that there are realistic data
generation mechanisms which satisfy this model. In addition, we have provided graphical and numerical
methods to assess the adequacy of the model.
When constructing the estimating function for model (2.1), we exclude the censoring by death from
the at-risk indicators. It seems counter-intuitive to regard a subject to be at risk after death. However, “at
risk” is a mathematical construct to ensure unbiased estimating functions. If there is no censoring by C ,
the composite endpoint process N ∗(·) will be fully observed. In that case, it is clear that censoring N ∗(·)
at D is mathematically wrong.
Regulatory submissions require the treatment efficacy be represented by a single parameter in the pri-
mary analysis. The rate (or mean) ratio for the weighted composite event process proposed in this article
satisfies this requirement and provides a fuller and more meaningful characterization of the clinical course
than the hazard ratio for the first composite event. It is sensible to combine death and life-threatening
recurrent events (e.g., heart failure or stroke) with appropriate weighting in the primary analysis.
The analysis based on the composite event process provides an overall assessment of the treatment effi-
cacy. A significant treatment effect on the composite endpoint does not imply significant treatment effects
on all its components. The existing methods that treat terminal and recurrent events as two separate end-
points can be used to determine the nature of the treatment effect. If the treatment reduces the frequencies
of both terminal and recurrent events, then its clinical benefits are clear. Because the occurrence of the
terminal event precludes further development of recurrent events, it is possible for the treatment to reduce
the risk of the terminal event and increase the incidence of recurrent events.
The choices of the weights will affect the power of statistical analysis and the interpretation of results.
If the treatment effect on the terminal event is similar to or smaller than the treatment effect on recurrent
events, then giving more weight to the terminal event than recurrent events will reduce statistical power, as
evident by the simulation results and the HF-ACTION study. On the other hand, a composite endpoint that
is dominated by recurrent events may not be of great interest to clinicians. One may choose the weights
in a data-adaptive manner such that the weight for the terminal event depends on how many patients have
experienced the terminal event. The weighting scheme should be specified a priory in consultation with
the appropriate drug approval agency and clinicians.
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SUPPLEMENTARY MATERIAL
Supplementary material is available online at http://biostatistics.oxfordjournal.org.
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